



England

National CYPDN Technology training day

Fulya Mehta
National Speciality Advisor
CYA Diabetes NHS England

National Paediatric Audit Data – Median HbA1c for CYP living with Type 1 Diabetes in England and Wales

Year on year improvement in HbA1c outcomes





Figure 5: Median HbA1c for children and young people with Type 1 diabetes in England and Wales, 2010/11 to 2023/24


Mean HbA1c for CYP with Type 1 diabetes using different combinations of diabetes treatment technology

NPDA 2022/23



Improved HbA1c outcomes with more sophisticated treatment technologies

13.4mmol/mol difference in mean HbA1c for CYP on HCL systems versus those using injection therapy alone



National HCL update



2025/26 Funding: The national funding available for ICBs this year has been confirmed at £59.5m, and indicative allocations for each ICB were shared in March 2025. This funding is ‘SDF’ which means it is ringfenced to support the roll out of HCL.

Updated HCL reimbursement guidance (shared 9th May via FutureNHS): Key updates included:

- An overview of the national funding available for 2025/26
- An explanation of the fixed allocation transferred to ICBs in May
- More detail on the original modelling used to calculate the national funding contributions
- How the reimbursement funding for each HCL start will be allocated
- Key dates for data submissions and payments


HCL has been included within the Saving Babies Lives Care bundle V3.2: To comply with the Clinical Negligence Scheme for Trusts Maternity Incentive Scheme (CNST MIS). Services should aim for >60% of pregnant women to be offered HCL in 2025/26 and >95% from 2026/27.

Data:

- ICBs and trusts will receive reports with Q4 activity data in June.
- The NPDA quarterly dashboard will be updated in June.
- **£100 per patient per year for administrative support**

Tech usage as at end Q3 2024/25

Proportion of people with Type 1 diabetes, England




Source: GIRFT analysis of NDA and NPDA data
Excludes those where tech status is unknown

Hybrid closed loop (HCL) users as at end Q3 2024/25

Proportion of people with Type 1 diabetes, England


0-18 years old 19-25 years old



Source: GIRFT analysis of NDA and NPDA data
Excludes those where tech status or ethnicity is unknown

Hybrid closed loop (HCL) users as at end Q3 2024/25 Proportion of people with Type 1 diabetes, England

■ 0-18 years old ■ 19-25 years old




Source: GIRFT analysis of NDA and NPDA data
Excludes those where tech status or deprivation is unknown

CGM users (including HCL and flash) as at end Q3 2024/25

Proportion of people with Type 1 diabetes, England


0-18 years old 19-25 years old



Source: GIRFT analysis of NDA and NPDA data
Excludes those where tech status or ethnicity is unknown

CGM users (including HCL and flash) as at end Q3 2024/25

Proportion of people with Type 1 diabetes, England



Source: GIRFT analysis of NDA and NPDA data
Excludes those where tech status or deprivation is unknown


HCL implementation learning from CYA GIRFT Diabetes Reviews

May 2025


Dr Nivedita Aswani, GIRFT Clinical Advisor for Children and Young Adults Diabetes
Dr Fulya Mehta, NHSE National Clinical Lead for Diabetes in Children and Young Adults
Professor Partha Kar, NHSE GIRFT Type 1 Diabetes Technology Clinical Lead
Professor Gerry Rayman, NHSE GIRFT Joint Diabetes Clinical Lead
Kim Howson, GIRFT Associate Workstream Delivery Manager
Sam Watson, GIRFT Workstream Delivery Officer




CYA GIRFT Programme – reducing unwarranted variation between ICBs and PDUs



Source: NPDA report care and outcomes 2023/24




Source: GIRFT analysis of NDA and NPDA data
Excludes those where tech status is unknown



Insights from GIRFT reviews and health inequalities technology projects

Commissioning, leadership and service structures:

- ICB HCL implementation plan with good clinical involvement and communication
- Funding transparency for diabetes technology
- Transition and young adult care services and pathways
- Standardised streamlined procurement pathways
- Clarity on BPT that enables adequate paediatric diabetes workforce



Insights from GIRFT reviews and health inequalities technology projects

Paediatric diabetes teams:

- Workforce including administrative support
- Data management systems
- Team ethos and culture
- HCP training and education
- Group technology starts
- Working with industry partners
- Virtual pumps starts and reviews (when appropriate)
- Novel roles – technology support workers and family support workers
- Optimisation of systems with clear HCL pathways and follow up

Hybrid closed loop system (%)

Percentage of children and young people with Type 1 diabetes using a hybrid closed loop system (HCL)
based on their most recent reported observation



Home

At a glance

Health checks

HbA1c median

Treatment targets

Insulin Pump

CGM

Closed loop system

DKA at diagnosis

DKA post diagnosis


DKA per 100 children

Benchmarking PDUs



England and Wales

Selected Organisation ● England and Wales (E&W)



Previous audit year results	2023/24 Q1	2023/24 Q2	2023/24 Q3	2023/24 Q4
England and Wales	17.5%	22.6%	28.3%	35.6%

Select organisation


Search

- ☐ 1.PDU
- ☐ 2.ICB/LHB
- ☐ 3.Networks
- ☐ 4.NHS regions
- ☐ 5.Country
- ☒ 6.England and Wales

cumulative


quarterly

Ethnicity




% of children using HCL
Selected Organisation ● E&W

Deprivation



% of children using HCL
Selected Organisation ● E&W

Age group



% of children using HCL
Selected Organisation ● E&W



England

Thank you

